Mini Review

Bromelain: A potential therapeutic application in SARS-CoV-2 infected patients

Serkan Sayiner1,2, Ayliz Velioğlu-Öğünç3 and Ahmet Özer Şehirli4*

1Department of Biochemistry, Faculty of Veterinary Medicine, Near East University, Nicosia, Cyprus
2Diagnostic Laboratory of Animal Hospital, Faculty of Veterinary Medicine, Near East University, Nicosia, Cyprus
3Vocational School of Health-Related Professions, Marmara University, Istanbul, Turkey
4Department of Pharmacology, Faculty of Dentistry, Near East University, Nicosia, Cyprus

Received: 26 April, 2021
Accepted: 18 June, 2021
Published: 19 June, 2021

*Corresponding author: Ahmet Özer Şehirli, Department of Pharmacology, Faculty of Dentistry, Near East University, Near East Boulevard Post Code: 99138, Nicosia, Cyprus, Tel: +90 392 680 20 30; E-mail: ahmetozer.sehirli@ineu.edu.tr

Keywords: Bromelain; Immunomodulation; Inflammation; ACE2; SARS-CoV-2; COVID-19

https://www.peertechzpublications.com

Abstract

The SARS-CoV-2 infection has led to a global pandemic which has led to almost 4 million deaths worldwide. However, to date, a specific antiviral drug does not exist to treat the disease and control the virus. Here, we focus on the potential use of bromelain in line with its anti-oxidant, anti-inflammatory, and immunomodulatory effects. Additionally, bromelain exerts fibrinolytic, anti-invasive and antithrombotic activities that may become a therapeutic candidate against SARS-CoV-2 infection. In this paper, we focused on bromelain’s therapeutic potential concerning its potential role in reducing the severity of symptoms and the adverse effects of other antiviral drugs currently being used. The therapeutic effects of bromelain suggests that it may reduce mortality and morbidity rates in patients with COVID-19 infections, through its anti-oxidant, anti-inflammatory, immunomodulator and anticoagulant effects. These positive effects leads us to propose that bromelain may be clinically valuable in the treatment of COVID-19 and that its therapeutic attributes should be fully investigated.

Background

Known as SARS-CoV-2, COVID-19 continues its negative impact on the world with its increasing morbidity and mortality rate [1]. Although the attempted control of the pandemic has been focused on the development of novel vaccine studies, the fact that the virus has reached a dangerous level through multiple mutations, there is necessity to develop newradical treatments and profolatic measures. The most critical factor limiting treatments is the negative potential for side effects due to the high doses of drugs delivered in the treatments so far [2]. For this purpose, the importance of immunomodulatory agents with high therapeutic index, which have anti-oxidant and anti-inflammatory properties, which can reduce the side effects of these drugs and play a role in the modulation of the immune system and prevent the devastating effects of a cytokine storm [3]. As a potential alternative treatment for COVID-19 we propose that bromelain, a phytotherapeutic drug, may provide an alternative solution.

Bromelain

Bromelain is a group of enzymes present in all parts of the pineapple plant (Ananas comosus), who’s enzyme’s first isolation was accomplished in 1891 [4,5]. Despite being found in all parts of the pineapple, extracts from the seed are commercially preferential. Bromelain extract is a mixture of different enzymes (thiol endopeptidases and phosphatase, glucosidase, peroxidase, cellulase), glycosidase-like components, carbohydrates, glycoproteins and several protease inhibitors.

Extensive data has been collected from numerous studies on the administration of large doses of bromelain, which are based on close or similar models, which have yielded varying results. Bromelain’s LD50 is >10 g/kg in rodents, 12 g/day orally is a safe dose for humans, without significant side effects [6,7].

Bromelain contains cysteine proteinases that have differences in proteolytic activity. It is unclear how bromelain
proteinases contribute to anti-inflammatory activity in vivo and is poorly absorbed when given orally, with resulting plasma levels less than 10 ng/ml in humans given 4 g/day [8,9].

**Bromelain and immunomodulation**

Bromelain is an immunomodulator with a pleiotropic effect [10]. It has been found to strengthen immunogenicity by increasing IFN-gamma and TNF alpha levels, significantly when the immune system is weakened [11]. In other studies, it has been reported that it inhibits mitogenesis, apoptosis and cytokine formation by preventing T cell activation in cases of inflammation, by blocking the Raf – 1/extracellular-regulated kinase (ERK)-2 pathway, through the reduction of CD4+ and CD25 expression [12,13].

In the studies conducted to date, through the CD4 and CD8 proteins in T cells of SARS-CoV-2 infection, interferon-gamma (IFN IL), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), nuclear factor kappa B (NF-κB) and tumour necrosis factor-α (TNF-α) have been found to increase the expression of cytokines [14,15]. Therefore, increased cytokine expression and the resulting tissue damage in COVID-19 is highly significant [16,17]. Thus, modulating cytokine levels both before and during the disease is the most critical way to combat COVID-19 infections [18–20].

The protective properties of bromelain have been demonstrated in both clinical and experimental inflammation models. It has achieved protective effects with its immunomodulatory, anti-oxidant and anti-inflammatory properties [21]. Therefore, it is likely that it may have a protective effect against free oxygen radicals and inflammatory cytokines, especially during COVID-19 infections (Figure 1). It has been reported that it may exert a protective effect through the inhibition of T cells-mediared IL-6 and TNF-α, an particularly during the cytokine storm seen in COVID-19 patients [22]. The various beneficial effects of bromelain which minimize tissue damage during viral infections suggest that it could play a supportive therapeutic role in treatment of COVID-19 infection. Slowing the onset of inflammation will also prevent the disease from escalating.

**Bromelain and its anticoagulant effect**

It has been reported that cytokines cause thrombosis by increasing platelet aggregation [23]. Bromelain inhibits platelet aggregation due to its suppression of proinflammatory cytokines [24]. It has been shown to suppress kinins synthesis during inflammation [13]. This is particularly important for increased quinine levels during COVID-19. Because kinins are effective in both inflammation and coagulation, where they have an important role in multiple organ damage during COVID-19 infections. Thus, it is possible that bromelain, with its anti-inflammatory and anticoagulant effect, can prevent multiple organ damage through its suppression of the increased quinine synthesis during COVID-19 infections.

Bromelain has plasminogen–plasmin mediated fibrinolytic effect [25]. It has been shown to prevent thrombosis by inhibiting platelet aggregation, primarily by increasing the plasmin concentration. Thrombosis and coagulation are important for ventilation and during COVID infections it causes respiratory problems in patients by reducing erythrocyte transport, [23].

---

**Figure 1:** SARS-CoV-2 causes tissue damage by increasing proinflammatory cytokines and reactive oxygen species. Bromelain administration may ameliorate tissue damage by decreasing cytokine levels as well as reactive oxygen species.

**Citation:** Sayiner S, Velioğlu-Öğüş A, Şehirli AO (2021) Bromelain: A potential therapeutic application in SARS-CoV-2 infected patients. Ann Antivir Antiretrovir 5(1): 015-018. DOI: https://dx.doi.org/10.17352/aaa.000011
Therefore, bromelain treatment is also important in terms of preventing coagulation and reducing respiratory distress.

**Bromelain and neuroprotective effect**

The analgesic and neuroprotective effects of bromelain are known [26]. The neurological symptoms of COVID-19 include headache, fever and fatigue [27]. Bromelain inhibits both kinins and PGE2 which is likely to improve these symptoms. Additionally, it has been reported that bromelain enables the anti-oxidant/oxidant balance to be realized in favour of the anti-oxidant by stimulating endogenous anti-oxidants and decreasing oxidants [26]. Hence, bromelain can limit tissue damage during COVID-19. Although there are limited number of studies related to bromelain’s antiviral effect, it can create a synergy with the adverse effects of additional antiviral drugs through its anti-oxidant and anti-inflammatory properties [21].

**Conclusion**

Bromelain, a phytotherapeutic drug and a crude proteolytic enzyme extracted from the pineapple plant with numerous beneficial properties [25], these include: preventing oedema formation, reduction of already-existing oedema in patients, anti-inflammatory and immunomodulatory effects [21,28,29]. Bromelain also contains different but closely-related proteinases that exerts anti-ooedematous, fibrinolitic, anti-invasive, and antithrombotic activities [25,30]. Enzyme extracts of bromelain modulate the functions of adhesion molecules on blood and endothelial cells, and also regulate and activate various immune cells and their cytokine production [25].

CoVID-19 is a serious viral disease that can lead to multiorgan failure and subsequent death through the disrupting effects of oxidative damage, cytokine storm and coagulation factors caused by the SARS-COV-2 virus. We suggest that in COVID-19 infection cases bromelain may reduce mortality and morbidity rates with its anti-oxidant, anti-inflammatory, immunomodulator and anticoagulant effects. Additionally, we propose that its use in combination with antiviral drugs may reduce mortality of studies related to bromelain’s antiviral effect, it can create a synergy with the adverse effects of additional antiviral drugs through its anti-oxidant and anti-inflammatory properties [21].

**Author contributions**

S. Sayner, A. Velioglu-Ogunc, and A. O. Şehirli had the idea for the article, performed literature search and data analysis. S. Sayner and A. Velioglu-Ogunc drafted the article and A. O. Şehirli critically revised the article.

**References**

1. Vardhana SA, Wolchok JD (2020) The many faces of the anti-COVID immune response. J Exp Med 217: e202009678. [Link](https://bit.ly/32FlhAj)
2. Aygün İ, Kaya M, Alhaji R (2020) Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep 10: 21508. [Link](https://https://bit.ly/3g5DYAM)
3. Jamilouly Y, Henry T, Belot A, Viol S, Fauter M, et al. (2020) Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev 19: 102567. [Link](https://https://bit.ly/3vJ008x)
4. Chittenden RH (1893) On the Proteolytic Action of Bromelin, the Ferment of Pineapple Juice. J Physiol 15: 249–310. [Link](https://bit.ly/3wLScGw)
5. Bhattacharyya BK (2008) Bromelain: An overview. Indian J Nat Prod Resour 7: 359-363. [Link](https://bit.ly/3cT3pMx)
6. Castell JV, Friedrich G, Kuhn CS, Pope GE (1997) Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 273: G139–G146. [Link](https://bit.ly/3gFjmib)
7. Hale LP (2004) Proteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of mice. Int Immunopharmacol 4: 255-264. [Link](https://bit.ly/3paBeaP)
8. Hale LP, Greer PK, Trinh CT, James CL (2005) Proteinase activity and stability of natural bromelain preparations. Int Immunopharmacol 5: 783–793. [Link](https://bit.ly/3zDaBXS)
9. Kelly G (1996) Bromelain: A Literature Review and Discussion of its Therapeutic Applications. Altern Med Rev 1: 243–257. [Link](https://bit.ly/3gEpC3Z)
10. Roep BO, van den Engel NK, van Halteren AGS, Duinkerken G, Martin S (2002) Modulation of autoimmunity to beta-cell antigens by proteases. Diabetologia 45: 686–692. [Link](https://bit.ly/3xUUIHC)
11. Engwerda CR, Andrew D, Murphy M, Mynott TL (2001) Bromelain activates murine macrophages and natural killer cells in vitro. Cell Immunol 210: 5–10. [Link](https://bit.ly/2S9UDDw)
12. Mynott TL, Ladhamas A, Scarmato P, Engwerda CR (1999) Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells. J Immunol 163: 2568–2575. [Link](https://bit.ly/35Bn15a)
13. Secor ERJ, Singh A, Guernsey LA, McNamara JT, Zhan L, et al. (2009) Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vivo. Int Immunopharmacol 9: 340–346. [Link](https://https://bit.ly/3zAAk4R)
14. Zhai Y, Wu B, Li J, Yao X, Zhu P, et al. (2016) CD147 promotes iKK/iKappaB/NF-kappaB pathway to resist TNF-induced apoptosis in rheumatoid arthritis synovial fibroblasts. J Mol Med 94: 71–82. [Link](https://bit.ly/3xk84fx)
15. Burslem GM (2021) The role of chemical biology in the fight against SARS-CoV-2. Biochem J 478: 157–177. [Link](https://bit.ly/3SAEMRB)
16. Saghasadeh A, Rezaei N (2020) Immune-epidemiological parameters of the novel coronavirus – a perspective. Expert Rev Clin Immunol 16: 465–470. [Link](https://bit.ly/3iU06GC)
17. Liu Y, Yan LM, Wan L, Xiang TX, Le A, et al. (2020) Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 20: 656–657. [Link](https://bit.ly/2FSfZI)
18. Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect 80: 607-613. [Link](https://bit.ly/3cSHexXP)
19. Fu Y, Cheng Y, Wu Y (2020) Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol J 17: 266–271. [Link](https://bit.ly/2Sb9ggq)
20. Zhang R, Wang X, Ni L, Di X, Ma B, et al. (2020) COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 250: 117583. [Link](https://bit.ly/2Um6YW9)
21. Rathnavelu V, Altheen NB, Sohila S, Kanagesan S, Namesh R (2016) Potential role of bromelain in clinical and therapeutic applications. Biomed Rep 5: 283–288. [Link](https://bit.ly/3vFL7G2)
22. Kakodkar P, Kaka N, Baig MN (2020) A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus 12: e7560. [Link](https://bit.ly/35AsSHl)
23. Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 8: e46-e47. [Link](https://bit.ly/2SLMDc3)
24. Errasti ME, Caffini NO, Pelzer LE, Rotelli AE (2013) Anti-inflammatory activity of Bromelia hieronymi: comparison with bromelain. Planta Med 79: 207–213. Link: https://bit.ly/3cSZ6i3

25. Maurer HR (2001) Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 58: 1234–1245. Link: https://bit.ly/2SBFQ4V

26. Bakare AO, Owoyele BV (2020) Antinociceptive and neuroprotective effects of bromelain in chronic constriction injury-induced neuropathic pain in Wistar rats. Korean J Pain 33: 13–22. Link: https://bit.ly/3gKfirv

27. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, et al. (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 7: 11. Link: https://bit.ly/3xrrzr4

28. Barrett A, Woessner J, Rawlings ND (2004) Handbook of Proteolytic Enzymes, Volume 1 2nd ed., Academic Press, Cambridge.

29. Muhammad ZA, Ahmad T (2017) Therapeutic uses of pineapple-extracted bromelain in surgical care - A review. J Pak Med Assoc 67: 121–125. Link: https://bit.ly/3gUic7

30. Pavan R, Jain S, Shraddha, Kumar A (2012) Properties and therapeutic application of bromelain: a review. Biotechnol Res Int 2012: 976203. Link: https://bit.ly/3gBfia2